title: Technical and safety aspects of blood and marrow transplantation using G-CSF mobilized family donors.
abstract: An allogeneic transplantation programme using immunoselected blood progenitor and bone marrow CD34+ cells has been established. Thirteen healthy HLA-matched, MLC negative sibling donors received two doses of 5 micrograms kg-1 G-CSF (s.c. daily) for 5 days. On days 4 and 5, large-volume mononuclear cell aphereses were performed (COBE Spectra) and on day 5 one unit of autologous blood was obtained. Mononuclear cells were pooled and cryopreserved after CD34+ cell-immunoselection on day 5. Bone marrow (BM) of the same donors was procured under routine conditions 10-45 days later (median: 27 days). The final graft consisted of blood CD34+ cells with either complete BM (n = 5) or immunoselected BM CD34+ cells (n = 8). The present paper describes the progenitor cell mobilization and apheresis protocol and analyzes the cell loss by BM and peripheral blood progenitor cell (PBPC) donation. Considerably larger amounts of mononuclear cells (CD45+), T-lymphocytes (CD3+) and platelets were lost by the apheresis as compared to bone marrow without apparent immediate clinical consequences for the donors. Owing to cross-cellular contamination of the apheresis concentrate, blood platelet count (PC) significantly decreased (mean PC after the second apheresis 116 x 10 microL-1); furthermore on average 3.04 x 10(10) CD3+ cells were removed by two apheresis sessions. This loss did not lead to long-term total lymphocyte count changes (2370 microL-1 versus 1889 microL-1) as observed during the long-term follow-up of 7/13 donors (mean 290 days). Subjectively, the PBPC collections were better accepted than BM donations in all but one family donor.
authors.affiliation: Blood Bank-Immunohematology-Transfusion Medicine, Medical School Hannover, Germany.
authors.forename: J G
authors.initials: JG
authors.lastname: Kadar
authors.forename: L
authors.initials: L
authors.lastname: Arseniev
authors.forename: K
authors.initials: K
authors.lastname: Schnitger
authors.forename: I
authors.initials: I
authors.lastname: Südmeier
authors.forename: M
authors.initials: M
authors.lastname: Zaki
authors.forename: K
authors.initials: K
authors.lastname: Battmer
authors.forename: R
authors.initials: R
authors.lastname: Jacobs
authors.forename: H
authors.initials: H
authors.lastname: Diedrich
authors.forename: H
authors.initials: H
authors.lastname: Poliwoda
authors.forename: W
authors.initials: W
authors.lastname: Stangel
authors.forename: H
authors.initials: H
authors.lastname: Link
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors